Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | PPIA | P62937 | 7/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29012769 | 0.98 | KMT2A (0.59) | KMT2AGAAMEN1LMNAMAPT | |
| SCHEMBL28763580 | 0.83 | GAA (0.45) | KMT2AGAAMEN1LMNAMAPT | |
| SCHEMBL7840846 | 0.82 | KMT2A (0.54) | KMT2AGAAMEN1LMNAMAPT | |
| SCHEMBL28603753 | 0.82 | KMT2A (0.54) | KMT2AGAAMEN1LMNAMAPT | |
| SCHEMBL28819896 | 0.81 | GAA (0.49) | KMT2AGAAMEN1LMNAMAPT | |
| SCHEMBL27523202 | 0.80 | MAPT (0.57) | KMT2AGAAMEN1LMNAMAPT | |
| SCHEMBL27819399 | 0.80 | KMT2A (0.78) | KMT2AMEN1POLB | |
| SCHEMBL144326 | 0.80 | KMT2A (0.65) | KMT2AGAAMEN1LMNAMAPT | |
| SCHEMBL29273709 | 0.79 | MAPT (0.65) | KMT2AMEN1LMNAMAPTTSHR | |
| SCHEMBL1007576 | 0.78 | MAPT (0.62) | KMT2AGAAMEN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114174291-A | 1,2, 4-oxadiazol-5-one derivatives for the treatment of cancer | 巴斯利尔药物国际股份公司 | 2022-03-11 | — | — | CN | claimed |
| US-8097750-B2 | Highly enantioselective, converting aromatic and aliphatic aldehydes into optically active aryl and alkyl beta -amino acids | BRANDEIS UNIVERSITY (US) | 2012-01-17 | — | — | US | claimed |
| CN-101558057-A | 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders | ACRAF (IT) | 2009-10-14 | — | — | CN | claimed |
| CN-101343302-A | Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives | SUPERGEN INC (GB) | 2009-01-14 | — | — | CN | claimed |
| CN-101282986-A | Oligonucleotide analogues incorporating 5-aza-cytosine therein | SUPERGEN INC (US) | 2008-10-08 | — | — | CN | claimed |
| US-20080228000-A1 | Cinchona Alkaloid-Catalyzed Asymmetric Mannich Reactions | BRANDEIS UNIVERSITY (US) | 2008-09-18 | — | — | US | claimed |
| CN-1894173-A | Preparation of 18-fluoro-labeled aromatic amino acids | UNIV EBERHARD KARLS (DE) | 2007-01-10 | — | — | CN | claimed |
| CN-1283637-C | Substd. N-Benzyl-indol-3-yl glyoxylic acid derivs. having anti-tumoral effect | ZENTARIS AG (DE) | 2006-11-08 | — | — | CN | claimed |
| CN-1852913-A | Synthesis and manufacture of pentostatin and precursors, analogs and derivatives thereof | SUPERGEN INC (US) | 2006-10-25 | — | — | CN | claimed |
| CN-1447805-A | Novel indole derivatives and their use as pharmaceuticals | ZENTARIS AG (DE) | 2003-10-08 | — | — | CN | claimed |
| CN-1420880-A | Substd. N-Benzyl-indol-3-yl glyoxylic acid derivs. having anti-tumoral effect | ZENTARIS AG (DE) | 2003-05-28 | — | — | CN | claimed |
| CN-1050545-A | Inhibitors of post-infective viral proteases | HOECHST AG (DE) | 1991-04-10 | — | — | CN | claimed |
| CN-110105434-B | Stapled and stitched polypeptides and uses thereof | 哈佛大学的校长及成员们 | 2024-09-17 | — | — | CN | disclosed |
| US-20240207414-A1 | DISULFIDE-BASED PRODRUG COMPOUND | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2024-06-27 | — | — | US | disclosed |
| WO-2024120466-A1 | MONOSACCARIDES, PHARMACEUTICAL COMPOSITIONS, AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | SURIO THERAPEUTICS CO., LTD (CN) | 2024-06-13 | — | — | WO | disclosed |
| CN-118059096-A | Methods of treating CNS disorders | 杭州高光制药有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-0208599-B1 | SUPPORTS, THEIR PREPARATION AND INTERMEDIATES OBTAINED, THEIR USE IN THE SYNTHESIS OF OLIGONUCLEOSIDES AND THE NUCLEOSIDES SO OBTAINED, AND OLIGONUCLEOTIDES LINKED TO THE SUPPORTS | ROUSSEL-UCLAF (FR) | 1989-08-30 | — | — | EP | disclosed |
| EP-0097994-B1 | METHOD FOR THE SOLID-PHASE SYNTHESIS OF RETRO-INVERSO POLYPEPTIDES | ENICHEM S.p.A. (IT) | 1987-09-30 | — | — | EP | disclosed |
| EP-0208599-A1 | Supports, their preparation and intermediates obtained, their use in the synthesis of oligonucleosides and the nucleosides so obtained, and oligonucleotides linked to the supports | ROUSSEL-UCLAF (FR) | 1987-01-14 | — | — | EP | disclosed |
| EP-0097994-A2 | Method for the solid-phase synthesis of retro-inverso polypeptides | ENICHEM S.p.A. (IT) | 1984-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207414-A1 | DISULFIDE-BASED PRODRUG COMPOUND | CBS, MSR1, P4HB | KMT2A 4713/4885GAA 2029/4885MEN1 3870/4885 |
| US-20080228000-A1 | Cinchona Alkaloid-Catalyzed Asymmetric Mannich Reactions | MANBA, MAN2A1, ASNS | KMT2A 607/4885GAA 288/4885MEN1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.